Volitionrx LTD VNRX
Institutional shares held
7.96 Million
39K
calls
0
puts
Total value of holdings
$5.34M
$26K
calls
$0
puts
Market Cap
$38.4M
57,297,000
Shares Out.
Institutional ownership
13.9%
# of Institutions
27
We take great care to ensure that the data presented and summarized in this overview for VOLITIONRX LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VNRX
View all-
Lagoda Investment Management, L.P. New York, NY5.07MShares$3.4 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA636KShares$426,2310.0% of portfolio
-
Geode Capital Management, LLC Boston, MA617KShares$413,6350.0% of portfolio
-
Black Rock Inc. New York, NY574KShares$384,4190.0% of portfolio
-
Cowen Prime Advisors LLC179KShares$119,7540.09% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX174KShares$116,7000.0% of portfolio
-
Silverberg Bernstein Capital Management LLC Armonk, NY145KShares$96,8940.11% of portfolio
-
Morgan Stanley New York, NY134KShares$89,7800.0% of portfolio
-
State Street Corp Boston, MA124KShares$83,0280.0% of portfolio
-
Northern Trust Corp Chicago, IL89.4KShares$59,8900.0% of portfolio
Latest Institutional Activity in VNRX
Top Purchases
Top Sells
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Insider Transactions at VNRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2024
|
Rodney Gerard Rootsaert Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
12,984
+10.53%
|
-
|
|
Jun 01
2024
|
Phillip Barnes |
BUY
Grant, award, or other acquisition
|
Direct |
8,011
+16.28%
|
-
|
|
Jun 01
2024
|
Nicholas Plummer GC - Volition Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
10,249
+7.11%
|
-
|
|
Jun 01
2024
|
Salvatore Thomas Butera CEO - Volition Veterinary |
BUY
Grant, award, or other acquisition
|
Direct |
31,256
+11.93%
|
-
|
|
Jun 01
2024
|
Terig Hughes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,686
+3.41%
|
-
|
|
Jun 01
2024
|
Kim Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
8,011
+12.98%
|
-
|
|
Jun 01
2024
|
Jasmine Kway CEO - Singapore Volition |
BUY
Grant, award, or other acquisition
|
Direct |
13,570
+10.28%
|
-
|
|
Jun 01
2024
|
Jacob Vincent Micallef Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,709
+11.98%
|
-
|
|
Jun 01
2024
|
Guy Archibald Innes |
BUY
Grant, award, or other acquisition
|
Direct |
16,022
+2.4%
|
-
|
|
Jun 01
2024
|
Michel Gaetan Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,689
+3.72%
|
-
|
|
Jun 01
2024
|
Gael Forterre Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,944
+6.12%
|
-
|
|
Jun 01
2024
|
Cameron John Reynolds President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
90,182
+4.66%
|
-
|
|
Jun 01
2024
|
Andrew Retter Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,326
+7.14%
|
-
|
|
Jun 01
2024
|
Alan Colman |
BUY
Grant, award, or other acquisition
|
Direct |
12,016
+5.7%
|
-
|
|
Jun 01
2024
|
Ann Louise Batchelor Group Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,685
+11.93%
|
-
|
|
May 23
2024
|
Andrew Retter Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
May 01
2024
|
Salvatore Thomas Butera CEO - Volition Veterinary |
SELL
Payment of exercise price or tax liability
|
Direct |
15,504
-7.21%
|
$0
$0.87 P/Share
|
|
Jan 24
2024
|
Kim Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+15.69%
|
-
|
|
Jan 24
2024
|
Jasmine Kway CEO - Singapore Volition |
BUY
Grant, award, or other acquisition
|
Direct |
28,475
+21.35%
|
-
|
|
Jan 24
2024
|
Jacob Vincent Micallef Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,375
+8.29%
|
-
|
Last 12 Months Summary
Buy / Acquisition
2.73M
Shares
From
30
Insiders
| Grant, award, or other acquisition | 1.53M shares |
|---|---|
| Bona fide gift | 1M shares |
| Open market or private purchase | 200K shares |
Sell / Disposition
1.11M
Shares
From
9
Insiders
| Bona fide gift | 1M shares |
|---|---|
| Payment of exercise price or tax liability | 73.2K shares |
| Open market or private sale | 40K shares |